Vincristine neuropathy in type I and type II charcot‐marie‐tooth disease (hereditary motor sensory neuropathy)
Medical and Pediatric Oncology1995Vol. 25(2), pp. 113–116
Citations Over Time
Abstract
A patient with Ewing's sarcoma and demyelinating type Charcot-Marie-Tooth disease (CMT) developed severe neuropathy after receiving a total vincristine dose of 6 mg. Recovery was slow and incomplete. A second patient with axonal type CMT developed moderate neuropathy but tolerated extended vincristine administration and recovered quickly. Possible underlying neuropathy should be excluded before vincristine treatment is begun by careful examination including inspection of the feet, followed by electrophysiologic studies as indicated. In demyelinating CMT, vincristine should be avoided; in axonal form cautious use may be considered.
Related Papers
- → Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening(2005)196 cited
- → Electrophysiologic Patterns of Symptomatic Vincristine-Induced Peripheral Neuropathy in Children with Acute Lymphocytic Leukemia(2023)6 cited
- → Possible enhancement of vincristine neuropathy by VP-16(1982)41 cited
- → Charcot-Marie-Tooth Disease (CMT, hereditary motor and sensory neuropathy)(2012)
- 4)Charcot-Marie-Tooth (CMT)病/hereditary motor and sensory neuropathy (HMSN)の臨床,病態および遺伝子異常(1995)